New era, new GOALs: cardiovascular screening and lipid management in cystic fibrosis.

ABSTRACT:

Background

Cardiovascular disease (CVD) risks are increasing in people with cystic fibrosis (pwCF). While cholesterol levels were historically low in pwCF, higher levels after initiating highly effective modulator therapy (HEMT) have been reported. Mechanisms are unclear and there is little guidance on screening.

Objectives

To evaluate serum lipid changes at multiple timepoints after ivacaftor initiation, and to assess current screening practices for CVD risk factors among CF providers.

Design

This was a post-hoc correlative analysis of prospectively collected clinical data and serum samples from the GOAL cohort study. Cross-sectional survey methodology was also employed.

Methods

We evaluated serum lipids (total cholesterol (TC), low-density lipoprotein (LDL),

SUBMITTER: Despotes KA 

PROVIDER: S-EPMC11786282 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature